Boston Scientific: Steady Growth Sparks Investor Excitement

Boston Scientific's stock surged nearly five percent after a blockbuster Q3 earnings report, exceeding expectations with over $5 billion in sales and a fifteen percent organic revenue jump. The medical device giant's consistent growth, up seventeen percent year-to-date, is boosting investor confidence and sparking speculation about whether it's the next steady performer akin to tech titans like Microsoft and Apple. Is now the time to buy?The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.